Sarwar Beg, PhD is currently serving as AMS-DBT Newton International Fellow at University of Central Lancashire, UK, and working in the area of glioblastoma research using targeted nanomedicines. He is also serving as the Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. He has over a decade of teaching and research experience in the field of pharmaceutics and biopharmaceutics, especially in the development of novel and nanostructured drug delivery systems using Quality-by-Design paradigms with core expertise in computational pharmaceutics, experimental designs and multivariate statistical techniques. He has authored over 200 publications, 60 book chapters, 15 books, 03 Indian patent applications and H-Index of 40 with over 5400 citations to his credit. Mahfoozur Rahman is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. He has authored more than 130 publications in peer-reviewed journals, 30 book chapters, seven books, and four articles in international magazines with various publishers. He has a Google Scholar h-index of 27 and over 1700 citations to his credit. He also serves on the editorial boards and as guest editor for several journals. He has received travel grants from various international congresses, such as IAPRD, MDS, Nano Today, KSN and WCN, on the basis of his research work and contribution in the field. Dr. Hani Choudhry is an Associate Professor of Genomics and the Head of Cancer and Mutagenesis Unit at the King Fahd Center for Medical Research in King Abdulaziz University (KAU), Saudi Arabia. Dr. Choudhry completed his DPhil in Clinical Medicine in Prof. Sir Peter Ratcliffe (Nobel Laureate 2019)’s lab at the Wellcome Trust Center for Human Genetics, University of Oxford, UK. Dr. Choudhry has received a number of international and prestigious awards including two AACR Scholar-in-Training Award, the Susan G. Komen for the Cure Award, the ASHG/Charles J. Epstein Trainee Award for Excellence in Human Genetics Research (SF), the Professional Achievement Award and the National Cancer Research Institute (NCRI) Prize Award. He was awarded by the British Embassy and the UAE International Genetic Disorders Prevention Award- Scientific Excellence Award in GCC. Dr. Choudhry’s current scientific interests focus on developing genomic technologies, and the integration of both clinical and pathological information with data generated from high-throughput molecular techniques. His work addresses the impact of genome and epigenome heterogeneity on the biology and clinical behaviour of diseases. In addition, he is leading a number of initiatives on artificial intelligence (AI) powered genome and drug discovery. Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a master’s in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry. Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.

• Section A: General consideration on cancer nanomedicines1. Nanomedicine for combinational anticancer drug therapeutics: Recent advances, challenges and future perspectives2. Market research in cancer therapeutics: New and Generic Product Development3. Regulatory perspectives of nanomedicines for cancer treatmentSection B: Formulation technologies in cancer nanomedicines4. Biopharmaceutical challenges in using lipid nanoparticles for oral chemotherapy5. Polymeric nanoparticles for potential drug delivery applications in cancer6. Lipid-polymer hybrid nanoparticles: Production, characterization and formulation of nucleic acids for cancer therapy7. Metallic nanoparticles in drug delivery and cancer treatment8. Liposomal nanotherapeutics in cancer treatment9. Surface decoration strategies in nanomedicines for cancer treatment10. Protein based nanomedicines as anticancer drug delivery platform11. Phyto actives loaded nanocarriers for liver cancer treatmentSection C: Innovative treatment strategies in cancer nanomedicines12. Nanotechnology assisted medical devices in cancer treatment13. Immunotherapy as a boon in cancer treatment14. Antibody-drug combination therapy in cancer treatment15. Immune-chemo combination therapy in cancer treatmentSection D: Clinical perspectives in cancer nanomedicines16. Formulation and biological stability of the nanomedicines in cancer treatment17. Nanotoxicology profiling of cancer nanomedicines18. Clinical translation status of nanoformulationsSection E: Regulatory perspectives in cancer nanomedicines19. GLP and cGMP requirements in the development of cancer nanomedicines20. Quality by Design approach for systematic development of nanopharmaceutical products

Sarwar Beg, PhD is currently serving as AMS-DBT Newton International Fellow at University of Central Lancashire, UK, and working in the area of glioblastoma research using targeted nanomedicines. He is also serving as the Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. He has over a decade of teaching and research experience in the field of pharmaceutics and biopharmaceutics, especially in the development of novel and nanostructured drug delivery systems using Quality-by-Design paradigms with core expertise in computational pharmaceutics, experimental designs and multivariate statistical techniques. He has authored over 200 publications, 60 book chapters, 15 books, 03 Indian patent applications and H-Index of 40 with over 5400 citations to his credit. Mahfoozur Rahman is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. He has authored more than 130 publications in peer-reviewed journals, 30 book chapters, seven books, and four articles in international magazines with various publishers. He has a Google Scholar h-index of 27 and over 1700 citations to his credit. He also serves on the editorial boards and as guest editor for several journals. He has received travel grants from various international congresses, such as IAPRD, MDS, Nano Today, KSN and WCN, on the basis of his research work and contribution in the field. Dr. Hani Choudhry is an Associate Professor of Genomics and the Head of Cancer and Mutagenesis Unit at the King Fahd Center for Medical Research in King Abdulaziz University (KAU), Saudi Arabia. Dr. Choudhry completed his DPhil in Clinical Medicine in Prof. Sir Peter Ratcliffe (Nobel Laureate 2019)’s lab at the Wellcome Trust Center for Human Genetics, University of Oxford, UK. Dr. Choudhry has received a number of international and prestigious awards including two AACR Scholar-in-Training Award, the Susan G. Komen for the Cure Award, the ASHG/Charles J. Epstein Trainee Award for Excellence in Human Genetics Research (SF), the Professional Achievement Award and the National Cancer Research Institute (NCRI) Prize Award. He was awarded by the British Embassy and the UAE International Genetic Disorders Prevention Award- Scientific Excellence Award in GCC. Dr. Choudhry’s current scientific interests focus on developing genomic technologies, and the integration of both clinical and pathological information with data generated from high-throughput molecular techniques. His work addresses the impact of genome and epigenome heterogeneity on the biology and clinical behaviour of diseases. In addition, he is leading a number of initiatives on artificial intelligence (AI) powered genome and drug discovery. Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a master’s in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry. Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.

• Section A: General consideration on cancer nanomedicines1. Nanomedicine for combinational anticancer drug therapeutics: Recent advances, challenges and future perspectives2. Market research in cancer therapeutics: New and Generic Product Development3. Regulatory perspectives of nanomedicines for cancer treatmentSection B: Formulation technologies in cancer nanomedicines4. Biopharmaceutical challenges in using lipid nanoparticles for oral chemotherapy5. Polymeric nanoparticles for potential drug delivery applications in cancer6. Lipid-polymer hybrid nanoparticles: Production, characterization and formulation of nucleic acids for cancer therapy7. Metallic nanoparticles in drug delivery and cancer treatment8. Liposomal nanotherapeutics in cancer treatment9. Surface decoration strategies in nanomedicines for cancer treatment10. Protein based nanomedicines as anticancer drug delivery platform11. Phyto actives loaded nanocarriers for liver cancer treatmentSection C: Innovative treatment strategies in cancer nanomedicines12. Nanotechnology assisted medical devices in cancer treatment13. Immunotherapy as a boon in cancer treatment14. Antibody-drug combination therapy in cancer treatment15. Immune-chemo combination therapy in cancer treatmentSection D: Clinical perspectives in cancer nanomedicines16. Formulation and biological stability of the nanomedicines in cancer treatment17. Nanotoxicology profiling of cancer nanomedicines18. Clinical translation status of nanoformulationsSection E: Regulatory perspectives in cancer nanomedicines19. GLP and cGMP requirements in the development of cancer nanomedicines20. Quality by Design approach for systematic development of nanopharmaceutical products

Sarwar Beg, PhD is currently serving as AMS-DBT Newton International Fellow at University of Central Lancashire, UK, and working in the area of glioblastoma research using targeted nanomedicines. He is also serving as the Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. He has over a decade of teaching and research experience in the field of pharmaceutics and biopharmaceutics, especially in the development of novel and nanostructured drug delivery systems using Quality-by-Design paradigms with core expertise in computational pharmaceutics, experimental designs and multivariate statistical techniques. He has authored over 200 publications, 60 book chapters, 15 books, 03 Indian patent applications and H-Index of 40 with over 5400 citations to his credit. Mahfoozur Rahman is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. He has authored more than 130 publications in peer-reviewed journals, 30 book chapters, seven books, and four articles in international magazines with various publishers. He has a Google Scholar h-index of 27 and over 1700 citations to his credit. He also serves on the editorial boards and as guest editor for several journals. He has received travel grants from various international congresses, such as IAPRD, MDS, Nano Today, KSN and WCN, on the basis of his research work and contribution in the field. Dr. Hani Choudhry is an Associate Professor of Genomics and the Head of Cancer and Mutagenesis Unit at the King Fahd Center for Medical Research in King Abdulaziz University (KAU), Saudi Arabia. Dr. Choudhry completed his DPhil in Clinical Medicine in Prof. Sir Peter Ratcliffe (Nobel Laureate 2019)’s lab at the Wellcome Trust Center for Human Genetics, University of Oxford, UK. Dr. Choudhry has received a number of international and prestigious awards including two AACR Scholar-in-Training Award, the Susan G. Komen for the Cure Award, the ASHG/Charles J. Epstein Trainee Award for Excellence in Human Genetics Research (SF), the Professional Achievement Award and the National Cancer Research Institute (NCRI) Prize Award. He was awarded by the British Embassy and the UAE International Genetic Disorders Prevention Award- Scientific Excellence Award in GCC. Dr. Choudhry’s current scientific interests focus on developing genomic technologies, and the integration of both clinical and pathological information with data generated from high-throughput molecular techniques. His work addresses the impact of genome and epigenome heterogeneity on the biology and clinical behaviour of diseases. In addition, he is leading a number of initiatives on artificial intelligence (AI) powered genome and drug discovery. Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a master’s in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry. Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.

• Section A: General consideration on cancer nanomedicines1. Nanomedicine for combinational anticancer drug therapeutics: Recent advances, challenges and future perspectives2. Market research in cancer therapeutics: New and Generic Product Development3. Regulatory perspectives of nanomedicines for cancer treatmentSection B: Formulation technologies in cancer nanomedicines4. Biopharmaceutical challenges in using lipid nanoparticles for oral chemotherapy5. Polymeric nanoparticles for potential drug delivery applications in cancer6. Lipid-polymer hybrid nanoparticles: Production, characterization and formulation of nucleic acids for cancer therapy7. Metallic nanoparticles in drug delivery and cancer treatment8. Liposomal nanotherapeutics in cancer treatment9. Surface decoration strategies in nanomedicines for cancer treatment10. Protein based nanomedicines as anticancer drug delivery platform11. Phyto actives loaded nanocarriers for liver cancer treatmentSection C: Innovative treatment strategies in cancer nanomedicines12. Nanotechnology assisted medical devices in cancer treatment13. Immunotherapy as a boon in cancer treatment14. Antibody-drug combination therapy in cancer treatment15. Immune-chemo combination therapy in cancer treatmentSection D: Clinical perspectives in cancer nanomedicines16. Formulation and biological stability of the nanomedicines in cancer treatment17. Nanotoxicology profiling of cancer nanomedicines18. Clinical translation status of nanoformulationsSection E: Regulatory perspectives in cancer nanomedicines19. GLP and cGMP requirements in the development of cancer nanomedicines20. Quality by Design approach for systematic development of nanopharmaceutical products